Clinical Trial Update: AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD). [Phase 2]

View source ↗

Summary

Phase IIa trial assessing efficacy, safety, and tolerability of oral AZD5718 in patients with coronary artery disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• AZD5718 (AZD5718)

Snippet

Sponsor: AstraZeneca | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-06-30